Nektar Therapeutics has initiated the first two studies in a 1,530-patient Phase 3 programme evaluating rezpegaldesleukin in adolescents and adults with moderate-to-severe atopic dermatitis, beginning the pivotal test of whether regulatory T-cell stimulation can compete with established eczema biologics and oral medicines.
ZENITH AD-1 and ZENITH AD-2 will each enroll approximately 510 patients who have not previously received a systemic biologic or Janus kinase inhibitor. A third trial, ZENITH AD-3, is expected to begin in September and will enroll another 510 patients who have already been treated with at least one of those systemic approaches.
The Nasdaq-listed biotechnology company expects initial Phase 3 results in mid-2028 and is targeting a Biologics License Application in 2029. Nektar Therapeutics designed the programme after completing an End-of-Phase 2 meeting with the U.S. Food and Drug Administration and receiving scientific advice from the European Medicines Agency.
Starting Phase 3 moves rezpegaldesleukin beyond an encouraging but still selectively interpreted mid-stage dataset. The pivotal studies must reproduce improvements in skin clearance and itching, establish safety across a much larger population and determine whether monthly or quarterly maintenance can preserve disease control after an initial course of injections every two weeks.
How will the three ZENITH-AD trials test induction, maintenance and prior treatment failure?
Each ZENITH-AD study contains a 24-week blinded induction period in which participants are randomized two to one to receive rezpegaldesleukin or placebo. The investigational biologic will be administered subcutaneously at 24 micrograms per kilogram every two weeks.
The first two trials focus on patients who are naive to systemic biologics and Janus kinase inhibitors. This creates a relatively controlled population in which rezpegaldesleukin is not being evaluated immediately after failure of another advanced therapy.
ZENITH AD-3 will provide a more demanding commercial test by enrolling treatment-experienced patients. These participants may include people who failed to respond adequately, lost response, experienced adverse effects or discontinued an earlier systemic treatment for another reason.
Separating these populations should make the results more interpretable. A medicine may perform strongly before exposure to another biologic but produce a weaker response in patients whose disease has already proved resistant to targeted treatment.
Patients who achieve at least a 75% improvement in their Eczema Area and Severity Index score, known as EASI-75, or an Investigator’s Global Assessment score of clear or almost clear at week 24 will proceed to a 28-week blinded maintenance period. They will be assigned in a two-to-two-to-one ratio to monthly dosing, quarterly dosing or placebo.
Participants who do not meet the response threshold will enter an open-label treatment escape arm. This component may provide information about whether some patients require longer exposure before reaching clinically meaningful skin clearance.
The maintenance design is particularly important. It will test whether less-frequent treatment preserves an established response and whether withdrawing active therapy causes control to deteriorate. That comparison should offer stronger evidence of durability than simply following patients who remain on uninterrupted treatment.
Why did Nektar choose skin clearance at week 24 as the pivotal efficacy test?
The primary endpoint for the United States is the proportion of patients achieving an Investigator’s Global Assessment score of zero or one at week 24, indicating clear or almost clear skin, together with the required improvement from baseline. EASI-75 is a key secondary endpoint for the U.S. programme.
For jurisdictions outside the United States, the Investigator’s Global Assessment and EASI-75 measurements will serve as co-primary endpoints. The distinction reflects differences in regulatory expectations while allowing the same global studies to support submissions in several markets.
Other important endpoints include EASI-90, representing at least a 90% reduction in disease severity, and a reduction of four or more points on the Itch Numeric Rating Scale. Patient-reported outcomes will examine whether visible improvements translate into less itching and better daily functioning.
Extending induction from 16 weeks in the Phase 2 study to 24 weeks in Phase 3 could work in Nektar Therapeutics’ favour if regulatory T-cell stimulation produces responses that deepen gradually. It also creates a more difficult comparison because placebo responses can increase during longer dermatology trials.
The magnitude of the difference will matter as much as statistical significance. Atopic dermatitis already has effective treatments, so a positive study cannot be evaluated as if patients had no advanced therapeutic options.
Clinicians will examine how many patients reach clear or almost clear skin, how rapidly itching improves and whether the treatment works consistently across geographic regions, disease severity levels and patient characteristics. The treatment-experienced trial may prove especially influential because persistent unmet need is often concentrated among patients who have already cycled through one or more systemic medicines.
What did the 393-patient REZOLVE-AD study establish before Phase 3 began?
The Phase 2b REZOLVE-AD study randomized 393 adults to receive one of three rezpegaldesleukin regimens or placebo for 16 weeks. The tested regimens included 24 micrograms per kilogram every two weeks, 18 micrograms per kilogram every two weeks and 24 micrograms per kilogram every four weeks.
All three active groups met the primary endpoint by producing statistically significant improvements in mean Eczema Area and Severity Index scores. Mean improvement reached 61% with the Phase 3-selected 24-microgram dose every two weeks, compared with 31% for placebo.
EASI-75 responses occurred in 42% of patients receiving the selected high-dose regimen and 17% receiving placebo. Clear or almost clear skin was reported in 20% and 8%, respectively. EASI-90 responses were achieved by 25% of the high-dose group and 9% of the placebo group.
An improvement of at least four points in itching was recorded in 42% of eligible high-dose patients, compared with 16% receiving placebo. The active-versus-placebo differences in these measurements support a genuine treatment effect, although the absolute response rates leave substantial room for improvement.
The 18-microgram group recorded a numerically higher EASI-75 response of 46% and a clear-or-almost-clear response of 26%. However, the 24-microgram regimen produced the strongest mean EASI improvement, EASI-90 response and itch reduction, contributing to its selection for Phase 3.
Cross-trial comparisons with approved medicines would be unreliable because patient populations, topical-treatment rules, endpoint handling and placebo responses differ. The pivotal programme must therefore establish rezpegaldesleukin’s profile directly, rather than depending on comparisons assembled from separate trials.
Does the Phase 2 maintenance analysis genuinely support quarterly eczema treatment?
After the initial 16 weeks, patients who had achieved at least EASI-50 were re-randomized to monthly or quarterly maintenance treatment through week 52. This responder-enriched design evaluated preservation and deepening of an existing response rather than performance across every patient originally randomized.
Among patients assigned to the pooled 24-microgram monthly regimen, 71% of those who had reached EASI-75 at the beginning of maintenance retained that response at week 52. The corresponding maintenance rate for quarterly dosing was 83%.
Approximately 85% of eligible monthly recipients and 63% of quarterly recipients maintained a clear-or-almost-clear Investigator’s Global Assessment response. Maintenance of the itch response reached 75% with monthly dosing and 77% with quarterly administration.
Some patients also developed deeper responses during maintenance. Across all re-randomized patients receiving the 24-microgram regimen, complete skin clearance measured by EASI-100 increased from 4% to 22% with monthly dosing and from 9% to 18% with quarterly dosing.
These figures are clinically interesting, but their denominators were much smaller than the original 393-patient study population. For several maintenance endpoints, the percentages were calculated from a limited number of responders who had already shown benefit during induction.
The findings therefore support the possibility of infrequent maintenance; they do not establish that most people starting treatment will eventually require an injection only once every three months. Phase 3 must first show how many patients qualify for maintenance and then determine how reliably each schedule preserves control.
The placebo-withdrawal component may become decisive. If patients moved from successful induction to placebo lose response substantially faster than those receiving monthly or quarterly injections, the study would offer stronger evidence that continued immune modulation is responsible for maintaining benefit.
Can regulatory T-cell stimulation offer something different from existing eczema medicines?
Rezpegaldesleukin targets the interleukin-2 receptor complex and is designed to preferentially expand regulatory T cells. These cells help restrain inappropriate immune activity and maintain tolerance to the body’s own tissues.
The therapeutic hypothesis is broader than blocking one inflammatory cytokine. Nektar Therapeutics is attempting to strengthen an immune-regulatory mechanism operating upstream of several inflammatory pathways involved in atopic dermatitis.
Phase 2 biomarker findings support on-target biological activity. Total regulatory T-cell levels increased by as much as sixfold in the highest-dose group, while reductions were observed in inflammatory markers including TARC/CCL17, periostin, MDC/CCL22 and interleukin-19.
Those changes do not prove that the medicine modifies the underlying course of atopic dermatitis. The pivotal endpoints measure skin clearance, disease severity and itching during treatment. They are not designed to demonstrate permanent correction of immune dysfunction.
Nektar Therapeutics expects separate off-treatment follow-up data from REZOLVE-AD in early 2027. Evidence that responses persist after treatment stops could strengthen the disease-modification argument, although uncontrolled durability would still need cautious interpretation.
For now, rezpegaldesleukin should be viewed as an investigational immune-modulating biologic with a novel mechanism, not as a confirmed immune reset. Phase 3 success would show that stimulating regulatory T cells can control disease symptoms. Demonstrating that it changes the long-term natural history of atopic dermatitis would require additional evidence.
How serious are injection reactions and other safety considerations for long-term use?
Injection-site reactions were the most frequent adverse events during the Phase 2 induction period, affecting approximately 69.7% of rezpegaldesleukin-treated participants. Almost all were classified as mild or moderate, and fewer than 1% of patients discontinued specifically because of an injection reaction.
The frequency is nevertheless commercially relevant. Atopic dermatitis is a chronic disease, and patients may be reluctant to continue an injectable treatment if nearly every administration produces noticeable local discomfort, swelling or redness.
Other adverse events occurring more often with rezpegaldesleukin than placebo included eosinophilia, fever, headache and joint pain. Serious adverse events occurred in five patients across the pooled active groups, including two events considered related to treatment. Both treatment-related serious events resolved.
Nektar Therapeutics did not observe an increased incidence of conjunctivitis, oral ulcers or infections, including oral herpes, during the 16-week analysis. A larger pivotal population will be better positioned to detect uncommon risks and establish whether immune-regulatory activity produces safety signals that were not evident in Phase 2.
The maintenance period produced no newly identified safety concern, while injection reactions reportedly became less frequent and were predominantly mild. Longer exposure across 1,530 participants remains necessary because an immune-modulating medicine may eventually be used for years rather than months.
Phase 3 also expands development into patients aged 12 and older who weigh at least 40 kilograms, whereas REZOLVE-AD enrolled adults. Regulators will examine adolescent exposure, adverse-event patterns and treatment discontinuations carefully before supporting a label that includes younger patients.
Can rezpegaldesleukin compete in an increasingly crowded atopic dermatitis market?
Rezpegaldesleukin would enter a market transformed by targeted biologics and oral Janus kinase inhibitors. Established options include dupilumab from Sanofi and Regeneron Pharmaceuticals, lebrikizumab from Eli Lilly and Company, tralokinumab from LEO Pharma and nemolizumab from Galderma.
Oral therapies such as upadacitinib from AbbVie and abrocitinib from Pfizer can produce rapid and substantial responses, but their labels contain safety warnings and require a different risk-benefit discussion from biologic treatment.
Nektar Therapeutics will need more than a novel mechanism. Rezpegaldesleukin must demonstrate competitive skin clearance, meaningful itch relief, manageable injection reactions and a maintenance schedule convenient enough to influence prescribing.
Quarterly maintenance could become a genuine advantage if confirmed. Less-frequent treatment may reduce administration burden and improve persistence, particularly among patients who dislike taking a medicine every day or injecting it every two weeks.
That potential advantage depends on successful induction. Patients would initially receive weight-based injections every two weeks for 24 weeks, which may be less convenient than fixed-dose biologics and more complicated than an oral tablet.
Weight-based dosing could also affect manufacturing demand, packaging and prescribing logistics. Nektar Therapeutics is developing rezpegaldesleukin for self-administration, but the company must demonstrate that patients and caregivers can deliver the correct dose consistently.
The treatment-experienced ZENITH AD-3 study may provide the clearest commercial answer. Strong results in patients who previously used a biologic or systemic Janus kinase inhibitor could position rezpegaldesleukin as a useful later-line option. Weak performance in that population could leave it competing primarily for patients who already have several effective first-line systemic choices.
Why does Nektar’s previous history with Eli Lilly still matter to this programme?
Nektar Therapeutics originally licensed rezpegaldesleukin to Eli Lilly and Company in 2017. The collaboration ended in 2023, after which Nektar regained full development and commercial rights.
Nektar Therapeutics subsequently said efficacy endpoints from earlier Phase 1b atopic dermatitis and psoriasis studies had been calculated incorrectly during the collaboration. The companies disputed responsibility for those errors through litigation.
That history created an unusual credibility burden for the programme. Clinical development temporarily became entangled with disagreements over data analysis, programme management and the termination of the partnership.
The independently conducted 393-patient REZOLVE-AD study reduced reliance on the disputed earlier dataset. Its randomized design, predefined endpoints and statistically significant results supplied a new evidentiary foundation for advancement.
Phase 3 must now remove the remaining uncertainty by producing results that can withstand regulatory review across three large, controlled studies. Reproducibility matters particularly for Nektar Therapeutics because investors have experienced major reversals across some of the company’s previous cytokine programmes.
Rezpegaldesleukin is distinct from bempegaldesleukin, the discontinued oncology candidate previously developed with Bristol Myers Squibb. The molecules, immune objectives, diseases and clinical programmes are different. Even so, Nektar Therapeutics’ history explains why the market may demand more evidence than one successful Phase 2 result before fully valuing another cytokine-based platform.
Does Nektar have enough capital to complete an unusually large pivotal programme?
Nektar Therapeutics reported $731.6 million in cash and marketable securities at March 31, 2026. That figure excluded approximately $351 million in net proceeds from an underwritten offering completed in April, taking pro forma liquidity above $1 billion before subsequent operating expenditure.
The company raised approximately $460 million in gross proceeds through a separate February offering and approximately $373.8 million through the April transaction. These financings materially strengthened its ability to fund Phase 3 without depending immediately on a new pharmaceutical partner.
They also diluted existing shareholders. Investors exchanged a smaller ownership interest for a balance sheet capable of supporting three 510-patient trials, an alopecia areata registration programme and continuing research in type 1 diabetes and earlier-stage immunology assets.
First-quarter research and development expenditure increased to $35.7 million from $30.5 million a year earlier as Nektar Therapeutics prepared for Phase 3. The company recorded a quarterly net loss of $44.9 million.
Spending will likely increase as international enrollment expands, clinical drug supply grows and the company prepares manufacturing, regulatory and commercial infrastructure. Initial data are not expected until mid-2028, leaving approximately two years of execution before the central efficacy question is answered.
The balance sheet substantially reduces near-term financing risk. It does not remove clinical risk or guarantee that existing capital will be sufficient through approval and commercial launch. A strategic partnership could still become attractive if Nektar Therapeutics wants to reduce launch costs or expand rezpegaldesleukin internationally.
What does the NKTR share-price response reveal about investor expectations?
Nektar Therapeutics shares traded near $66.64 shortly before noon Eastern Time on July 21, approximately 2.8% above the previous closing price of $64.84. The stock had opened near $64.42 and reached an intraday high of approximately $66.71.
The positive but restrained response suggests that investors welcomed confirmation of Phase 3 execution without treating the announcement as an unexpected clinical catalyst. Nektar Therapeutics had already guided that the programme would begin by July, and the two initial studies had appeared in clinical-trial registries before the formal announcement.
The shares were approximately 0.8% below their July 14 close of $67.17 and about 1.4% above the June 22 close of $65.70. The near-flat five-session and one-month performance indicates that the trial launch did not materially change the market’s prior assessment of rezpegaldesleukin.
The longer-term movement is much more dramatic. NKTR remained within a 52-week range of approximately $21.02 to $109. At the July 21 price, the shares were more than three times the range low but about 39% below the high.
Sentiment is constructive but highly dependent on clinical execution. The company is valued at roughly $2.2 billion following the recent equity offerings, meaning investors already assign substantial value to rezpegaldesleukin despite the absence of Phase 3 results or commercial product revenue from the programme.
The next major catalysts include off-treatment REZOLVE-AD durability data in early 2027, the planned alopecia areata Phase 3 start, initial type 1 diabetes findings and evidence that all three ZENITH-AD studies are recruiting as intended.
Which Phase 3 outcomes would make rezpegaldesleukin a credible new eczema treatment?
A credible Phase 3 outcome requires successful Investigator’s Global Assessment and EASI-75 results across both treatment-naive trials, supported by meaningful EASI-90 and itch responses. Consistency between ZENITH AD-1 and ZENITH AD-2 will be essential because one positive trial accompanied by a materially weaker replication would complicate regulatory interpretation.
ZENITH AD-3 must show whether the mechanism retains value after another advanced treatment has failed. This could become the most commercially informative part of the programme even if the treatment-naive studies provide the principal evidence for registration.
Safety must remain acceptable as exposure expands from 393 adults to 1,530 adolescents and adults. Injection reactions will require particular attention, alongside eosinophilia, systemic symptoms, serious events and any infections or immune-related complications emerging during longer follow-up.
The maintenance analysis must demonstrate that monthly and quarterly administration reliably preserve response. Quarterly dosing could distinguish rezpegaldesleukin in an increasingly competitive market, but only if the benefit is supported by adequate patient numbers and a clear advantage over treatment withdrawal.
Nektar Therapeutics has sufficient capital, regulatory alignment and encouraging Phase 2 evidence to justify the pivotal investment. What it does not yet have is proof that regulatory T-cell stimulation can deliver the efficacy, convenience and long-term safety required to change atopic dermatitis prescribing.
ZENITH-AD is designed to supply that answer. If the programme succeeds across induction, maintenance and treatment-experienced populations, rezpegaldesleukin could establish the first major commercial role for a regulatory T-cell agonist in chronic inflammatory disease. If it falls short, a novel mechanism and an unusually strong balance sheet will not compensate for inadequate skin clearance or durability.
